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Mastitis is a common disease responsible for the biggest economic loss in 
the dairy industry. Antibiotic therapy does not provide long-term protection. 
And residue is a major concern in food safety. Vaccination is an alternative 
control method with great potential for bovine mastitis. Our study focus on 
evaluating vaccine efficacy regarding reducing the incidence of clinical and 
subclinical mastitis. Meta-analysis was used to pool data extracted from 
previous studies. 26 records from 13 studies were examined. A fixed effect 
model was constructed assigning incidence as the measurement of the 
outcome. Risk ratio (RR) was the parameter that measured the incidence 
differences between treated group and control group. Studies and records 
were categorised based on vaccine antigens. In vaccine against Staphylo-
coccus aureus, RR was 0.76; 95% CI (0.65,0.89), while in vaccine against 












Mastitis is inflammation in quarters of the udders and the most significant cause of economic loss in dairy industry which manifests as reduced 
milk yield, milk composition change, reduced quality, 
and compromised reproduction capacity [1]. Current main-
stream control method is prepartum antibiotic therapy 
with very limited long-term effects in reducing somatic 
cell counts (SCC) and increased milk yield. Bacterial 
antibiotic resistance and drug residues in dairy products 
could be the inherent risks. Vaccination function as a con-
trol method by generating long lasting immunity against 
offending pathogens in dairy cow, and does not have 
withdrawal time, which makes it a promising alternative 
protocol to the established ones [2.3,4]. Vaccination could be 
helpful as an aid for prevention of a few bacteria.
The search for effective vaccine can trace back to last 
century and positive result was not reported until 1980s. 
A vaccine, combining heat-killed capsular-type A and B 
Staphylococcus aureus and capsular polysaccharide, was 
reported to increase the resistance against Staphylococ-
cus aureus in dairy cows, and mitigated mastitis related 
yield reduction [5]. About the same time, the investigation 
on vaccine against Escherichia coli also produced some 
positive results. J5 antigen was proven to reduce incidents 
of clinical coliform mastitis [6]. However, conflicting re-
sults were also reported. Some researchers argued that 
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vaccines had no effect on alleviating clinical parameters 
like incidence rate, SCC and commercial parameters like 
yield loss and culling rate [7,8,9,10]. The failure of vaccine 
in combating mastitis could be attributed to the multiple 
causative pathogens [8,11], low mammary antibody titer [12], 
environmental factors and ect.
A previous report proposed that the implement of vac-
cination had some advantages [12]. With the release of the 
new commercial vaccine and data from new clinical trials, 
it is necessary to re-evaluate the mastitis vaccine efficacy 
and its potential application. 
2. Methods
2.1 Literature Search Strategy
The literature search was conducted in Pubmed electronic 
database, Web of Science, in January 2018. The Medical 
Subject Heading (Mesh) and keywords for disease and 
intervention were searched in [All Fields] using various 
combinations. The search terms for disease were mastitis 
OR "bovine mastitis" and search terms for intervention 
were vaccine* OR vaccination*. For example, the search-
ing strategy in Pubmed was (((Mastitis"[Mesh]) OR 
"Mastitis, Bovine"[Mesh])) AND (("Vaccination"[Mesh]) 
OR "Vaccines"[Mesh]). To supplement computer search, a 
manual search for possible articles was also conducted by 
searching references of identified articles. 
The searching result was imported into Endnote X8. 
Duplicates were eliminated by cross check author’s name, 
article’s title and the publication year. 
2.2 Inclusion and Exclusion Criteria
Studies using controlled trials and observational method 
like cohort study and case-control study were included. 
Controlled trails must consist both randomized controlled 
trials (RCT) and controlled clinical trials (CCT). Other 
inclusion criteria are: (1) participant of the study were dry 
or lactating cows; (2) intervention was vaccination; (3) 
control groups were unvaccinated or treated with placebo; 
(4) outcomes must include the incidence of mastitis; anti-
biotic treatment as control group.
2.3 Date Extraction
Trial duration, vaccination regimens and outcome measure 
methods were extracted. In studies containing multiple 
trials, if summation was available, the data in summation 
were extracted and all trials were considered as one study; 
if summation was not available, multiple-center trial was 
considered as one study or the data of trials were extracted 
separately. 
2.4 Quality Assessment
The quality of RCT was assessed for the risk of bias by the 
Cochrane Collaboration’s tool. Cochrane Collaboration’s 
tool contains following items: random sequence generation, 
allocation concealment, blinding of participants and person-
nel, blinding of outcome assessment, incomplete outcome 
data, selective reporting and other bias. The first and sec-
ond items assess selection bias. The third and fourth items 
assess performance bias. The fifth item assesses detection 
bias and the sixth item assesses reporting bias.
The quality of CCT was assessed by MINORS (meth-
odological index for non-randomized studies) [13]. MI-
NORS is particularly suitable for the evaluating non-ran-
domized studies. There are 12 items measured in 0~2 
(0 for no related report, 1 for insufficient report, 2 for 
sufficient report). The top eight items were for the uncon-
trolled groups and the rest were for the study with control 
groups. The last item was excluded because it assesses the 
statistical analysis method, while in our study, the extract-
ed data were re-analyzed to calculate RR.
2.5 Assessment of Risk of Bias
Depending on the type of a trial, various tools were used 
to assess risk of bias.
2.6 Statistic Analysis
Risk ratio was used to estimate the outcome of each trial. 
We used STATA 14.0 to pool results with a fixed effect 
model. Heterogeneity was evaluated by Chi2 and I2. If 
I2 is below 25%, then it indicates low heterogeneity. If I2 
is above 75%, it indicates high heterogeneity. When high 
heterogeneity was observed, data were pooled by adopt-
ing a random model. Sensitive analysis was conducted by 
omitting one study each time, evaluating the influence of 
each study on the overall effect size (RR) and the source of 
heterogeneity. Bias was assessed and presented by a funnel 
plot. The symmetry of the funnel plot revealed the extent of 
bias. A study with no bias is perfectly symmetrical. We in-
cluded both subjective visual assessment and the objective 
Egger’s test. The latter was conducted via the meta com-
mand in STATA 14.0 to quantitatively assess symmetry of 
the funnel plot and publication bias. If the p-value in each 
test was below 0.1, the plot was deemed asymmetric. 
A subgroup analysis was conducted to evaluate the influ-
ence of the sample size. Datum was divided into two sub-
groups based on the calculated result of the sample size at the 
beginning of the analysis. The formula was shown below:
n = 2
(µ µα β+ −
( )P P1 0−
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P0 was the incidence in vaccinated group. P1 was the 
incidence in control group. μa and μb were t-value of type 
one error and type two error when df=∞. 
3. Results
The literature search in electronic databases initially 
identified 323 studies, 279 studies were from Pubmed, 
34 studies were from Sciencedirect and 10 studies from 
manual search. 10 duplications were eliminated. 245 
studies were excluded after we examined their titles and 
abstracts. Then full-article sift-selection was conducted 
on the remaining 68 studies to verify eligibility. 58 studies 
were excluded for following reasons: 25 studies measured 
the outcome in methods incompatible to our established 
criteria such as the concentration of antibodies, SCC, milk 
yield, pathogens in milk samples and etc. 4 studies were 
conducted in species other than bovine, like goats and 
mice. 2 studies did not utilize vaccination as intervention. 
2 studies had no control groups. 1 study was case control 
study. 8 studies were experimental challenge trial. Data 
in 12 studies could not be extracted. 2 studies have other 
incompatible objectives (Figure 1).
 
313 records after 10 duplicates removed 242 records excluded 
Records identified through 
database searching 
(n=313) 
Additional records identified 
through manual search 
(n=10) 
68 records screened 
10 full-text articles assessed for eligibility 
58 full-text articles excluded with reasons: 
Conducted in other animals:4 
Other interventions:2 
No control group:2 
Case-control study:1 
Other outcome measure:25 
Experimental challenge trial:8 
Other topic:2 
Unextractable data:12 
Figure 1. Flow chart search strategy
The selected studies presented the outcome with two 
methods, three were measured by prevalence while seven 
were measured by the number of cases. The duration of 
date recording ranged from 30DIM to 120DIM. The char-
acteristics of the records were shown in Table 1. Different 
vaccination protocols were used, six of them used label 
regime while others used modified protocols (Table 2). The 
data extracted was represented in table form (Table 3a, 3b).
Table 1. Characteristics of studies included in meta-analysis
First Authors Origin of Vaccine





(2017,a) Startvac Blank Control
1.Incidence of Clini-
cal Mastitis




(2017,b) Startvac Blank Control
1. Incidence of Clin-
ical Mastitis












(2011) E. coli Blank Control
Incidence of Clini-
cal Mastitis CCT
Wilson (2007) E. coli Blank Control Incidence of Clini-cal Mastitis CCT
Tenhagen 











(1996,a) S. aureus Blank Control






(1996,b) S. aureus Blank Control














(1989) E. coli Blank Control
Incidence of Clini-
cal Mastitis RCT
Table 2. Immunization protocols of studies included in 
meta-analysis
First Authors Immunization Procotol Immunization Route
Guccione 
(2017,a)
45 and 10 days before the esti-








On the day of recruitment (d 0), 
28 d later (d 28), 62 d thereafter 
(d 90), and then every 90 d until 
the end of the study.
Intramuscular 
Injection
Bradley (2015,b) Label regime Intramuscular Injection
Morimoto 
(2011)
On the day of recruitment (d 0), 




Before cows were dried off to 
end the previous lactation and 









5 and 2 weeks before the esti-
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Watson (1996,a) The last trimester of pregnancy Intramuscular Injection
Watson (1996,b) The end of the previous lactation Intramuscular Injection
Nordhaug 
(1994)
8 and 2 weeks before the esti-




The first injection at drying off






The first injection at drying off,
the second one in 28 days later




Label regime: the first injection, 45 days before the predicted calving; the 
second injection, 35 days later (10 days before the predicted calving date); 
the third injection, 62 days later (52 days after the predicted calving date)
Table 3a. Date extracted from studies (vaccine against 
Staphylococcus aureus), including duration, the number 
of bovines in vaccinated group and control group
First Author Duration
Vaccinated Group Control Group
+ - Total + - Total
Clinical Mastitis
Guccione(2017,a) 3M 2 28 30 2 28 30
Guccione(2017,a) 3M 0 30 30 0 30 30
Bradley(2015,a) 4M 8 550 558 8 568 576
Bradley(2015,b) 4M 10 405 415 8 568 576
Tenhagen(2000) 3M 67 97 164 74 83 157
Hodemaker(2000) — 5 30 35 6 30 36
Watson(1996,a) 9M 41 634 675 62 663 725
Watson(1996,b) 9M 4 167 171 5 149 154
Nordhaug(1994) — 9 49 58 10 40 50
Subclinical Mastitis
Guc-
cione(2017,A) 3M 4 26 30 3 27 30
Guc-
cione(2017,B) 3M 6 24 30 12 18 30
Hodemaker(2000) — 19 16 35 16 20 36
Total 202 2219 2421 268 2352 2620
Table 3b. Date extracted from studies (vaccine against 
Escherichia coli), including duration, the number of bo-
vines in vaccinated group and control group
First Author Observation Time
Vaccinated Group Control Group
+ - Total + - Total
Clinical Mastitis
Bradley (2015,a) 4M 63 495 558 57 529 576
Bradley (2015,b) 4M 48 367 415 57 529 576
Morimoto 
(2011) 10M 54 181 235 50 195 245
Subclinical Mastitis
Wilson (2007) 20M 27 224 251 15 291 306
Mc Clure (1994) 5M 49 597 641 78 568 646
Gonzailez 
(1989) — 6 227 233 29 198 227
Total 429 2501 2930 470 2706 3156
Note: M = month
Six RCT were included in the analysis. The result of 
quality evaluation was presented in Figure 2. Three out 
of six studies conducted random sequence generation and 
were evaluated as low risk [14,15,16]. Among these three 
studies, two utilized random number table and one utilized 
coin flipping. The rest did not report relevant information 
and therefore were deemed as unclear risk [17,7,9].
Figure 2. Qualification assessment of studies included
None of these six studies reported relevant information 
of whether allocation concealment was applied, therefore 
all of them were deemed as unclear risk.
Four studies completed blinding of participant and per-
sonnel [16,14,8,9]. Among these four studies, one coded vac-
cine and placebo in order to bind participant and person-
nel and other three studies reported clearly that participant 
and personnel knew nothing about allocation. The rest two 
studies provided no information relevant to this evaluation 
item and therefore were deemed as unclear risk [15,17].
Six studies completed blinding of outcome assessment. 
The participant and personnel of the four studies men-
DOI: https://doi.org/10.30564/vsr.v2i1.1929
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tioned above also conducted outcome assessment and 
therefore were evaluated as low risk. Other two studies 
assessed the outcomes by clinical symptoms, SCC, bac-
terial culture and therefore the process of the outcome 
assessment were considered objective.
All six studies reported complete outcome data. Informa-
tion regarding exclusion of participants during the exper-
iment and its reason was presented clearly. All six studies 
have no bias of selective reporting or bias of other types.
Four CCT were included. The result of quality assess-
ment was shown in the table 4. The total scores ranged 
from 13 to 17. For 6th item, four out of six studies scored 
1 for the lack of explicit standards of time monitoring. 
Only one study conducted objective evaluation of masti-
tis. No study estimated sample size.
Table 4. Qualification assessment of studies included 
using MINORS
Author ○1 ○2 ○3 ○4 ○5 ○6 ○7 ○8 ○9 ○10 ○11 total
Guccione 
(2017) 2 2 2 2 2 1 2 0 0 2 2 17
Morimoto 
(2011) 2 2 2 1 0 1 2 0 0 2 2 14
Wilson (2007) 2 2 2 0 0 1 2 0 0 2 2 13
Tenhagen 
(2001) 2 2 2 0 0 1 2 0 2 2 2 13
The pathogen in seven studies was Staphylococcus au-
reus. Twelve groups of datum were extracted from these 
seven studies. 4530 cows were included after pooling, 
2166 of them were vaccinated, and 2364 received placebo 
or no treatment. One group of datum was excluded be-
cause the incidence in both vaccinated and control group 
was zero, and RR was not available. Low heterogeneity 
between was observed with I2=0% (Figure 3). The overall 
RR was 0.86(0.72, 1.02). 
Figure 3. A forest plot of risk ratios and 95% confidence 
intervals for 12 records assessing the efficacy of Staphylo-
coccus aureus vaccines
The pathogen in five studies was Escherichia coli. Six 
groups of datum were extracted from these seven studies. 
4914 cows were included after pooling, 2338 of them 
were vaccinated, and 2576 cows received placebo or no 
treatment. High heterogeneity between was observed with 
I2=82.8% (Figure 4). The overall RR was 0.96 (0.81, 
1.12). 
Figure 4. A forest plot of risk ratios and 95% confidence 
intervals for 6 records as-sessing the efficacy of Esche-
richia coli vaccines
Each dot in the funnel plot represents a set of data. 
Data with larger sample size were allocated to the higher 
position on the diagram. The funnel plot of Staphylococ-
cus aureus vaccine was visually symmetrical (Figure 5), 
while the funnel plot of Escherichia coli vaccine was vi-
sually asymmetrical (Figure 6). The result of Egger’s test 
was consistent with visual assessment, with p-value 0.642 
and 0.614 respectively (Table 5,6). 
Figure 5. A funnel plot illustrating the deviation of me-
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Figure 6. A funnel plot illustrating the deviation of me-
ta-analysis assessing the efficacy of Escherichia coli 
vaccines
Based on the parameters set in the previous study, 
the incidence of mastitis in vaccinated group and con-
trol group was assumed as 0.125 and 0.25 respectively, 
the probability of testing type one error was assumed as 
10%(α=0.1), the probability of testing type two error was 
assumed as 80%(1-β), therefore the μa and μb was 1.645 
and 1.282. So the minimum sample size was 167. 
The subgroup analysis revealed that sample size had no 
influence on the conclusion of the efficacy of the Staph-
ylococcus aureus vaccine with RR 0.87(0.72, 1.07) and 
0.86(0.72, 1.02) respectively (Figure 7). The sample size 
of all study in Escherichia coli vaccine group was larger 
than 167, thus subgroup analysis was not conducted.
Figure 7. A forest plot of subgroup analysis assessing the 
influence of sample size
The result of sensitive analysis revealed that the con-
clusion of the efficacy of the Staphylococcus aureus vac-
cine was not stable. When two of twelve data sets were 
omitted, the pooling result converted to a positive conclu-
sion with 95% CI excluding value 1 (Table 7). Contrarily, 
the conclusion of the efficacy of the Escherichia coli vac-
cine was stable for no conversion of the conclusion was 
detected (Table 8). 
4. Discussion
The aim of this meta-analysis was to assess the efficacy of 
vaccine against mastitis caused by Staphylococcus aureus 
or Escherichia coli through pooling previous studies. The 
overall effect indicates that vaccination does not provide 
significant protection against bovine mastitis caused by 
Staphylococcus aureus or Escherichia coli with RR 0.86 
at 95% CI [0.72,1.02] and 0.96 with at 95% CI [0.81,1.12] respec-
tively, both showing the inclusion of the value 1 in the CI.
The results of quality assessment revealed half of 6 
randomized controlled trials mentioned the “random” in 
the description, but failed to specify the method of random 
allocation, and compromised the quality of the study. One 
study allocated cows based on ear tags (odd number and 
even number was divided into two groups). Although this 
practice reduces the workload, it cannot be considered as 
an appropriate randomising method. The process of ran-
dom allocation consists two main steps. The first step is 
the generation of random sequences. Multiple methods are 
available to achieve this goal, such as the random number 
table method and SAS. The generated random sequence is 
to be used as a random allocation scheme. The next step 
is to conceal allocation, and prevent personnel from con-
sciously or unconsciously influencing the experiment out-
come. Appropriate randomization can reduce the individ-
ual’s impact on the results. For example, self-resolution 
is possible in mastitis, and will affect the evaluation of 
vaccine efficacy. However, this ability is different among 
individuals, and relevant factors include immune status 
and genetic resistance. Appropriate random allocation re-
duces the influence of these factors, and increases the ac-
curacy of results. The results of a study without allocation 
concealment can be exaggerated by 30%-41% comparing 
to those with allocation concealment.
Some studies did not report whether the participants 
were blind to the treatment. Unlike human clinical trials, 
animals are inherently considered as blind participants un-
der most circumstances, as a result, personnel are the only 
concern in this aspect. The blind method is implemented 
to ensure everyone involved in the experiment is unaware 
of the precise allocation plan, and preserves the impartial-
ity of the evaluation. Pereira also pointed out in his sys-
tematic review that some trials may conceal true efficacy 
of vaccines due to the lack of double-blind measures [11]. 
This reminds the necessity of comprehensive design and 
detailed description regarding random allocation method 
DOI: https://doi.org/10.30564/vsr.v2i1.1929
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in future studies. 
It is also important to cover economic factor in future 
studies. The cost-profit analysis should cover the impact 
of withdraw period, productivity loss, and vaccination 
cost, for dairy industry is primarily profit driven. Ozsvari 
conducted a survey in a large-scale Hungarian dairy farm 
which initiated Startvac® application in 2010. The survey 
reported that the mastitis vaccination increased average 
annual profit by € 50.7 (decrease in loss-cost of vacci-
nation) per cow between 2011 and 2014 [18]. Although 
Startvac® is not effective in reducing incidence, it may 
have a significant positive impact on reducing the quantity 
of discarded milk. Our meta-analysis suggested that the 
polyvalent inactive mastitis vaccine.
5. Conclusions 
The results in this study revealed the efficacy of vaccine 
against mastitis caused by Staphylococcus aureus or Esch-
erichia coli. The overall effect indicates that vaccination 
does not provide significant protection against bovine 
mastitis caused by Staphylococcus aureus or Escherichia 
coli.
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